Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Better Buy: Gilead Sciences vs. Biogen

TheMotleyFool

0 0

Investing in blue-chip pharmaceutical stocks can relieve some stress during recessions. For example, shares of Gilead Sciences (NASDAQ: GILD) closed trading Monday up 13.7% year to date, compared with a 5% decline for the broad-market S&P 500 index. Meanwhile, shares of Biogen (NASDAQ: BIIB) have declined by about 6% in 2020, but may rebound sharply due to solid business performance.

With Gilead Sciences marketing a newly authorized treatment for COVID-19 and Biogen developing a novel treatment for Alzheimer's disease, investors' expectations for both stocks are high. But which of the two companies is a better buy today?

Image Source: Getty Images.

Source Fool.com

Like: 0

GILD

Share